Playback speed
10 seconds
ASCO 2022 on GEOMETRY-N Trial: Neoadjuvant and Adjuvant Capmatinib in Resectable NSCLC With MET Exon 14 Skipping Mutation or High MET Amplification
By
ASCO 2022 Conference Coverage
FEATURING
Jay Lee
By
ASCO 2022 Conference Coverage
FEATURING
Jay Lee
961 views
June 8, 2022
Comments 0
Login to view comments.
Click here to Login